Maxim Group Initiates Coverage On Acrivon Therapeutics with Buy Rating, Announces Price Target of $24

marketspectator_a43xh6 October 5, 2023

Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.

Administrator

Visit Website View All Posts

You must be logged in to post a comment.

Related Stories